EWA
BCAX

EverSource Wealth Advisors’s Bicara Therapeutics BCAX Stock Holding History

EverSource Wealth Advisors’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19K Sell
40
-275
-87% -$6.14K ﹤0.01% 3910
2026
Q1 		$6.27K Buy
315
+6
+2% +$103 ﹤0.01% 3160
2025
Q4 		$5.2K Sell
309
-60
-16% -$1.02K ﹤0.01% 3105
2025
Q3 		$5.83K Buy
369
+291
+373% +$3.26K ﹤0.01% 3091
2025
Q2 		$724 Sell
78
-24
-24% -$286 ﹤0.01% 3808
2025
Q1 		$1.33K Buy
+102
New +$1.35K ﹤0.01% 3109

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EverSource Wealth Advisors's BCAX Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Bicara Therapeutics (BCAX) stake by 87% in Q2 2026, selling an estimated $6.14K and leaving 40 shares worth $1.19K. The position accounts for ﹤0.01% of the portfolio, ranked #3910.

EverSource Wealth Advisors first reported a position in BCAX in Q1 2025 and has held it in 6 quarters since. The position peaked at $6.27K in Q1 2026. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • EverSource Wealth Advisors held 40 shares of Bicara Therapeutics worth $1.19K as of Q2 2026.
  • EverSource Wealth Advisors sold 275 Bicara Therapeutics shares in Q2 2026, an estimated $6.14K.
  • Bicara Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3910 holding.
  • EverSource Wealth Advisors first reported a position in Bicara Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • EverSource Wealth Advisors's Bicara Therapeutics position peaked at $6.27K in Q1 2026.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.